Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ) announced that it has received an acceptance notice from the National Medical Products Administration for its clinical trial application. The innovative small molecule drug SAL0137 (project code: SAL0137), independently developed by the company, has had its clinical trial application accepted. SAL0137 has independent intellectual property rights and is an oral small molecule drug developed by the company. The submitted application is for the clinical trial of SAL0137 in the treatment of elevated lipoprotein(a).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments